Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks
I'm PortAI, I can summarize articles.
Cathie Wood's ARK Invest is pivoting towards genomic stocks, anticipating a significant genomic revolution by 2026. The firm has sold off legacy stocks like Tesla to invest heavily in gene-editing companies such as CRISPR Therapeutics, Beam Therapeutics, and Pacific Biosciences. Wood emphasizes the synergy between AI and biology, predicting that advancements in AI will enhance gene sequencing and drug development. By late 2025, ARK's holdings in these companies will significantly increase within its flagship ARKK Innovation Fund and the Ark Genomic Revolution Fund.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments